142 related articles for article (PubMed ID: 24814803)
41. The potential prognostic value of cathepsin D protein in serous ovarian cancer.
Chai Y; Wu W; Zhou C; Zhou J
Arch Gynecol Obstet; 2012 Aug; 286(2):465-71. PubMed ID: 22476353
[TBL] [Abstract][Full Text] [Related]
42. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
43. Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions.
Elstrand MB; Stavnes HT; Tropé CG; Davidson B
Hum Pathol; 2012 Apr; 43(4):529-35. PubMed ID: 21864883
[TBL] [Abstract][Full Text] [Related]
44. Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions.
Davidson B; Berner A; Trope' CG; Wang TL; Shih IM
Hum Pathol; 2007 Jul; 38(7):1030-1036. PubMed ID: 17391728
[TBL] [Abstract][Full Text] [Related]
45. Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome.
Davidson B; Holth A; Moripen L; Trope' CG; Shih IeM
Hum Pathol; 2011 Jul; 42(7):991-7. PubMed ID: 21315424
[TBL] [Abstract][Full Text] [Related]
46. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
Sherman-Samis M; Onallah H; Holth A; Reich R; Davidson B
Gynecol Oncol; 2019 Jun; 153(3):651-660. PubMed ID: 30904337
[TBL] [Abstract][Full Text] [Related]
47. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
Davidson B; Alejandro E; Flørenes VA; Goderstad JM; Risberg B; Kristensen GB; Trope CG; Kohn EC
Cancer; 2004 May; 100(10):2139-47. PubMed ID: 15139056
[TBL] [Abstract][Full Text] [Related]
48. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
49. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
Broner EC; Tropé CG; Reich R; Davidson B
Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
[TBL] [Abstract][Full Text] [Related]
50. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
51. Soluble AXL is ubiquitously present in malignant serous effusions.
Flem Karlsen K; McFadden E; Flørenes VA; Davidson B
Gynecol Oncol; 2019 Feb; 152(2):408-415. PubMed ID: 30448261
[TBL] [Abstract][Full Text] [Related]
52. MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival.
Hetland TE; Nymoen DA; Emilsen E; Kærn J; Tropé CG; Flørenes VA; Davidson B
Gynecol Oncol; 2012 Sep; 126(3):460-5. PubMed ID: 22652154
[TBL] [Abstract][Full Text] [Related]
53. nm23 expression in malignant ascitic effusions of serous ovarian adenocarcinoma.
Simone G; Falco G; Caponio MA; Campobasso C; De Frenza M; Petroni S; Wiesel S; Leone A
Int J Oncol; 2001 Nov; 19(5):885-90. PubMed ID: 11604983
[TBL] [Abstract][Full Text] [Related]
54. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.
Lohneis P; Darb-Esfahani S; Dietel M; Braicu I; Sehouli J; Arsenic R
Anticancer Res; 2015 Nov; 35(11):6329-34. PubMed ID: 26504072
[TBL] [Abstract][Full Text] [Related]
55. GATA6: a new predictor for prognosis in ovarian cancer.
Shen W; Niu N; Lawson B; Qi L; Zhang J; Li T; Zhang H; Liu J
Hum Pathol; 2019 Apr; 86():163-169. PubMed ID: 30633927
[TBL] [Abstract][Full Text] [Related]
56. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.
Davidson B; Reich R; Lazarovici P; Nesland JM; Skrede M; Risberg B; Tropé CG; Flørenes VA
Clin Cancer Res; 2003 Jun; 9(6):2248-59. PubMed ID: 12796393
[TBL] [Abstract][Full Text] [Related]
57. Significance of adhesion molecules expression for estimation of serous ovarian cancer prognosis.
Ryabtseva OD; Lukianova NY; Shmurakov YA; Polishchuk LZ; Antipova SV
Exp Oncol; 2013 Sep; 35(3):211-8. PubMed ID: 24084461
[TBL] [Abstract][Full Text] [Related]
58. Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma.
Davidson B; Shih IeM; Wang TL
Hum Pathol; 2008 Nov; 39(11):1630-6. PubMed ID: 18656238
[TBL] [Abstract][Full Text] [Related]
59. Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma.
Brunetti M; Holth A; Panagopoulos I; Staff AC; Micci F; Davidson B
Virchows Arch; 2019 Feb; 474(2):177-185. PubMed ID: 30467600
[TBL] [Abstract][Full Text] [Related]
60. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
